193 related articles for article (PubMed ID: 8998950)
21. Comparison of three physiologically based pharmacokinetic models of benzene disposition.
Bois FY; Woodruff TJ; Spear RC
Toxicol Appl Pharmacol; 1991 Aug; 110(1):79-88. PubMed ID: 1871774
[TBL] [Abstract][Full Text] [Related]
22. A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans.
Seng KY; Vicini P; Nestorov IA
Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6485-8. PubMed ID: 17959432
[TBL] [Abstract][Full Text] [Related]
23. Evaluating parameter availability for physiologically based pharmacokinetic (PBPK) modeling of perfluorooctanoic acid (PFOA) in zebrafish.
Khazaee M; Ng CA
Environ Sci Process Impacts; 2018 Jan; 20(1):105-119. PubMed ID: 29265128
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based pharmacokinetic model for quinocetone in pigs and extrapolation to mequindox.
Zhu X; Huang L; Xu Y; Xie S; Pan Y; Chen D; Liu Z; Yuan Z
Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2017 Feb; 34(2):192-210. PubMed ID: 28001497
[TBL] [Abstract][Full Text] [Related]
25. Physiologically-based pharmacokinetic model for evaluating gender-specific exposures of N-nitrosodimethylamine (NDMA).
Kang DW; Kim JH; Choi GW; Cho SJ; Cho HY
Arch Toxicol; 2024 Mar; 98(3):821-835. PubMed ID: 38127128
[TBL] [Abstract][Full Text] [Related]
26. Uncertainty and variability in the exposure reconstruction of chemical incidents--the case of acrylonitrile.
Huizer D; Ragas AM; Oldenkamp R; van Rooij JG; Huijbregts MA
Toxicol Lett; 2014 Dec; 231(3):337-43. PubMed ID: 25050995
[TBL] [Abstract][Full Text] [Related]
27. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
28. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.
McLanahan ED; El-Masri HA; Sweeney LM; Kopylev LY; Clewell HJ; Wambaugh JF; Schlosser PM
Toxicol Sci; 2012 Mar; 126(1):5-15. PubMed ID: 22045031
[TBL] [Abstract][Full Text] [Related]
29. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
Krishnan K; Johanson G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
[TBL] [Abstract][Full Text] [Related]
30. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.
Krauss M; Burghaus R; Lippert J; Niemi M; Neuvonen P; Schuppert A; Willmann S; Kuepfer L; Görlitz L
In Silico Pharmacol; 2013; 1():6. PubMed ID: 25505651
[TBL] [Abstract][Full Text] [Related]
31. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
32. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform.
Tan YM; Liao KH; Conolly RB; Blount BC; Mason AM; Clewell HJ
J Toxicol Environ Health A; 2006 Sep; 69(18):1727-56. PubMed ID: 16864423
[TBL] [Abstract][Full Text] [Related]
33. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
34. Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations.
Weijs L; Roach AC; Yang RS; McDougall R; Lyons M; Housand C; Tibax D; Manning T; Chapman J; Edge K; Covaci A; Blust R
Chemosphere; 2014 Jan; 94():91-6. PubMed ID: 24080004
[TBL] [Abstract][Full Text] [Related]
35. Bayesian population analysis of a washin-washout physiologically based pharmacokinetic model for acetone.
Mörk AK; Jonsson F; Johanson G
Toxicol Appl Pharmacol; 2009 Nov; 240(3):423-32. PubMed ID: 19660484
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.
Tsiros P; Bois FY; Dokoumetzidis A; Tsiliki G; Sarimveis H
J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):173-192. PubMed ID: 30949914
[TBL] [Abstract][Full Text] [Related]
37. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.
Al-Subeihi AA; Alhusainy W; Kiwamoto R; Spenkelink B; van Bladeren PJ; Rietjens IM; Punt A
Toxicol Appl Pharmacol; 2015 Mar; 283(2):117-26. PubMed ID: 25549870
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output.
Farrar D; Allen B; Crump K; Shipp A
Toxicol Lett; 1989 Dec; 49(2-3):371-85. PubMed ID: 2690411
[TBL] [Abstract][Full Text] [Related]
40. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
